Observational studyRespiratory research2023

The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6-11 with cystic fibrosis in a real-world setting.

Paul McNally et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.